Introduction
Since the da Vinci TM surgical system (Intuitive Surgical Inc., Mountain View, CA, USA) was introduced [1, 2] , it has enabled more delicate surgery with three-dimensional vision, seven degrees of freedom, breakthrough accuracy and improved access to the surgical field. In many studies, robotic surgery has proved to be a safer alternative to other surgical methods and is now used as standard [3, 4] . In 2000, Intuitive Surgical had only 18 da Vinci TM surgical systems worldwide. By 2016, there were more than 3 700 surgical systems in use worldwide and more than 3 000 000 robotic surgical procedures were performed (Intuitive Surgical Annual Report 2016) [5] . It has been debated, however, whether robotic surgery is cost-effective and whether it is necessary [6] .
In Korea, the Meere Company Inc. has been developing a new robotic surgical system since 2006 (Model MSR-5000;
Meere Company Inc, Yongin, Republic of Korea). In the last 2 years, the Revo-i â Model MSR-5000 has been applied safely in various preclinical studies of partial nephrectomy, cholecystectomy and Fallopian tube surgery in live porcine models [7] [8] [9] . The Korean Food and Drug Administration (KFDA) approved clinical use of the Revo-i robotic surgical system after successful results of preclinical studies.
The aim of the present study was to evaluate the safety and feasibility of this new system in the treatment of patients with localized prostate cancer (PCa). To our knowledge, this is the first human study of robot-assisted radical prostatectomy (RARP) using the Revo-i robotic platform.
Materials and Methods

Ethical Standards
Use of the Revo-i in humans in the present prospective study was approved by the KFDA (No.14, 2016-04-26) and the Yonsei University Health System, Severance Hospital institutional review board (1-2016-0019) . We informed fully and discussed all possible complications with patients and their families. If malfunction of the working machine occurred, we were ready to complete the surgical procedure using another Revo-i surgical system or the da Vinci TM surgical system.
Study Design
Between 17 August 2016 and 23 February 2017, 17 patients with clinically localized PCa were included and treated using a Retzius-sparing (RS)-RARP approach. All surgeries were performed by an expert surgeon (K.H.R.) in RARP who had performed >1 300 standard RARP surgical procedures and >400 RS-RARP surgical procedures before starting the study. The console surgeon, two bedside assistants (K.D.C. and A.A.R.), and four robotic surgery nurses participated in the present study and were fully trained on how to use the Revoi from their previous experience in the animal studies [7, 9] .
Clinicopathological Variables
Patients' baseline, clinical and pathological characteristics were collected: age, BMI, prostate volume, biopsy Gleason score, American Society of Anesthesiologists (ASA) score, PSA, neoadjuvant hormonal therapy, clinical stage, positive surgical margin (PSM), pathological stage, and pathological Gleason score. The following intra-operative variables were recorded: any reported complications; docking time; operating time; console time; urethrovesical anastomosis time; estimated blood loss (EBL); and blood transfusion.
Postoperative Follow-up
Postoperative follow-up was conducted to ensure a smooth recovery course. Hospital stay, duration of catheterization, and any degree of complications according to Clavien-Dindo classification were reported. Early continence and oncological outcomes were evaluated at 3 months after surgery. All patients were fully continent before surgery; continence was assessed using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short-Form questionnaire [10] . Continence was defined as use of no pads or one safety pad per day. Patients who used more than one pad per day were considered incontinent. PSM status was defined as the presence of tumour cells at the inked margin of the prostatic specimen. PSA was measured at 1 and 3 months after surgery, and biochemical recurrence (BCR) was defined as two consecutive elevations of serum PSA > 0.2 ng/mL.
Physicians' Survey on Satisfaction with Robotic Surgery
Physicians' questionnaires were administered after surgery. Physician questionnaire items included the convenience of porting and docking, the convenience of inserting and removing robotic instruments, the discomfort of the robotic procedure, the convenience of the console and video monitor, the fatigue associated with the operation procedure, and the operation time appropriateness, based on a Likert scale [11] . Answers were scored as follows: strongly disagree (1 point); disagree (2 points); neither agree nor disagree (3 points); agree (4 points); and strongly agree (5 points).
Outcome Measures
The primary endpoint was the intra-operative performance and safety of Revo-i in the treatment of patients with PCa using the RS-RARP approach, and the successful completion of the surgery without conversion to da Vinci, open or laparoscopic surgery. A video describing the new robotic surgical system and step-by-step RS-RSRP surgery is provided (Video S1). Secondary endpoints were the postoperative recovery course, as well as, early oncological and continence outcomes.
Preoperative Preparations
All patients fasted prior to surgery (at least 8 h), and an enema was administered on the night preceding the day of surgery. A single i.v. dose (1 g) of third-generation cephalosporin was given. All patients wore protective leg stockings during the surgery.
Robotic Surgical System
The Revo-i robotic surgical system is a master-slave robot system (Fig. 1) . It consists of a surgeon control console, a four-arm robotic operation cart, a high-definition vision cart, and reusable endoscopic instruments. The Revo-i robotic
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© 2018 The Authors BJU International © 2018 BJU International surgical system was described in detail in previous reports [7, 9] . The difference between the Revo-i (Model MSR-5000) and the da Vinci surgical system specifications are shown in Table 2 .
Patient Positioning
The patient was placed on the operating table in the lithotomy position, and was secured to the table with adhesive tape. Gel support with padding was applied to all pressure points. The abdomen was draped in the usual sterile manner. A 12-mm supraumbilical vertical skin incision was made. The fascia and peritoneum were opened and a camera trocar was inserted. CO 2 gas was infused to create a pneumoperitoneum up to a pressure of 20 mmHg, later dropped to 12-15 mmHg. The table was tilted to a 30°Trendelenburg position with overextension of the pelvis.
Robotic Instruments and Ports
The Revo-i robotic platform has four robotic arms: one arm (B) is attached to a 12-mm supraumbilical camera port and the three working robotic arms: arm (A) is attached to an 8-mm port, arm (C) and (D) are attached to 12-mm ports. We used the following robotic instruments: a Maryland bipolar grasper in arm A; monopolar scissors in arm C; a prograsper in arm D; and two large-needle drivers in arms A and C during urethrovesical anastomosis. The four working ports were inserted under laparoscopic vision. Two assistant 12-and 5-mm ports were used to allow a bimanual bedside assistant (Fig. 2) .
Surgical Steps
The surgical steps are listed below.
• Mobilization of the colon. We used a 0°lens. The sigmoid colon was freed and reflected medially from its attachment to the lateral abdominal wall. Then, we mobilized the bowels cranially to expose the rectovesical space.
• Posterior peritoneal incision. The peritoneum of the rectovesical space was incised horizontally slightly above the level of the vas deferens.
• The vas deferens was mobilized and clipped bilaterally.
• Seminal vesicle dissection. The plane between the seminal vesicles and the surrounding tissue was developed and any vessel was secured with 5-mm clips before its division. We tried to minimize thermal use posterolateral to the seminal vesicle.
• Posterior prostatic dissection. Both seminal vesicles and vas deferens were pulled upwards with the grasper to develop the plane between the Denonvilliers' fascia and the posterior prostatic fascia. Suction by the bedside assistant helped during this step. The dissection was continued to reach the prostate-urethral junction. At this point, the neurovascular bundle was freed from the posterior prostatic aspect.
• Lateral prostatic dissection and sparing of the neurovascular bundle. Starting from one side, prostatic dissection was carried out circumferentially from the posterolateral aspect of the prostate towards the anterolateral aspect and from the bladder neck distally towards the apex of the prostate. We used a combination of sharp and blunt dissection. Nerve-sparing was undertaken based on individual surgeon discretion according to clinical disease stage, patient age and patient's sexual function. We minimized the use of coagulation, and any vessels were clipped and divided. Dissection was continued distally until the dorsal vascular complex and the lateral urethral aspect were visible. The dissection was repeated on the opposite side. At this point, the lateral and posterior prostatic aspects were freed.
• Dissection of the bladder neck. We identified the prostatovesical junction as follows: (i) a notch between the prostate and bladder; (ii) dissection of the peri-vesicle fat around the bladder neck carefully until we saw the detrusor muscles; and (iii) downward prostatic traction to tent the bladder neck. Using sharp scissor cutting, the detrusor muscles at the level of the bladder neck were cut and the bladder was entered posteriorly. The anterior bladder mucosa was divided and the anterior bladder neck was retracted anteriorly to dissect the anterior prostatic aspect up to dorsal vascular complex. Usually we do not control the dorsal vascular complex as we dissect the avascular plane between the dorsal vascular complex and the urethra. The urethra was further dissected and divided a few mm distal to the prostatic notch.
• Vesico-urethral anastomosis. The Maryland bipolar forceps and scissors were replaced with two needle drivers. Vesicourethral anastomosis was performed with two 3/0 absorbable barbed monofilament polyester sutures. We started from the right side, at the 12 o'clock position, by suturing the anterior bladder neck to the anterior urethra margin using the running suture technique until the 3 o'clock position. Then we repeated the procedure on the left side starting from the 11 o'clock and moving to the 9 o'clock position. At this point, an 18-F Foley catheter was inserted into the bladder and anastomosis of the posterior bladder neck and urethra was continued bilaterally until both sutures met at the 6 o'clock position. A new 18-F silicone catheter was inserted and its balloon inflated with 10 mL water. Both suture ends were tied together and a water-tight closure was confirmed with 150 mL saline.
• Closure of peritoneal incision. We routinely closed the peritoneal incision using 3/0 Barbed Monofilament Polyglyconate absorbable sutures (Covidien, V-LOC TM 180). The pelvic drain was inserted under vision through the 5-mm assistant port. .6 (3.1-10.7) ng/mL, respectively. Nine, five and three patients had clinical stages T1-T2a, T2b-T2c and T3a disease, respectively. Five, six, one and five patients had preoperative Gleason scores 6, 7 (3 + 4), 7 (4 + 3) and 8-10, respectively. Three patients received neoadjuvant hormonal therapy. Eleven patients underwent bilateral nerve-sparing, three unilateral, and three no nervesparing. No pelvic lymph node dissection (PLND) was performed (Table 1) .
Peri-operative Outcomes
The median (IQR) operating time, docking time, console time and urethrovesical anastomosis time were 186 (163-200) min, 8 (7-11) min, 92 (85.5-133) min and 26 (23-31) min, respectively. The median (IQR) EBL was 200 (200-300) mL and intra-operative transfusion was performed only in one patient. In this case, there was severe adhesion around the prostate and EBL was 1 500 mL; however, the patient's recovery in the general ward followed the same course as that of other patients. There were no major complications of Clavien-Dindo grade ≥3. One patient had mild fever and two patients were transfused because of a decrease in postoperative serum haemoglobin of <10 mg/dL. The median (IQR) postoperative hospital stay was 4 (4-7) days. Four patients wanted to stay in hospital until removal of the Foley catheter. No postoperative complications were seen (Table 1) .
Early Oncological and Continence Outcomes
Four patients had PSMs in the final pathological specimen. PSM sites were at the apex (one patient), posterior left (one patient), anterior (one patient) and seminal vesicle (one patient). The distribution of pT2 and pT3 stage was 94.1% and 5.9%, respectively. When stratified according to pathological stage, PSM rates were 3/16 patients and 1/1 patient with pT2 and pT3, disease, respectively. At 3 months, only one patient met the definition of BCR and we performed stricter follow-up of this patient in case adjuvant hormonal therapy was required. Regarding urinary continence, the continence rate, defined as use of no pad or one safety pad, was 58.8% at 1 week and 82.4% at 1 month. At 3 months, 12 patients were completely dry, three patients were using one safety pad, and two patients were using two pads or more (Table 1) . 
Physicians' Satisfaction with the Revo-i Robotic Surgical System
According to the surveys, physicians felt most comfortable in porting and docking, found the console and video monitor convenient, and were satisfied with the appropriateness of the total operating time ( Table 3) .
Discussion
This is the first clinical trial to evaluate the safety and feasibility of the Korean robotic surgical system Revo-i for treatment of patients with localized PCa. All RS-RARP procedures were performed successfully without major intra-operative complications, organ injury or conversion to da Vinci, open or laparoscopic conversion. There were no major complications of Clavien-Dindo grade ≥3. Early oncological and continence outcomes were encouraging. The postoperative survey showed that most patients would agree to undergo robotic surgery again if another surgical treatment was needed, and physician discomfort level was moderate on the Likert scale.
The Revo-i robotic surgical system has been in development since 2005. The first prototype was introduced in 2007. The Korean Ministry of the Knowledge Economy selected this project for development of a surgical robotic system. Many prototypes were developed in which function and performance were improved. During this period, several preliminary animal studies were performed, and updated models were stabilized and have shown good function [7] [8] [9] . The preclinical study was performed with these animal models successfully, and approval for the clinical application of the robotic surgical system from the KFDA was given to us in 2016.
In February 2017, a clinical trial was performed successfully and this new robotic surgical system was licensed commercially in August 2017. Prostatectomy was carefully chosen as the first procedure to be used as a functional test of the Revo-i robotic surgical system for the following reasons. Prostatectomy is currently the most popular surgery in the field of robotic surgery. It requires high performance and it is an ideal surgery to evaluate delicate function of new robotic system. Moreover, RS-RARP is more surgically demanding compared with the standard RARP approach because of the narrow working space, especially with large prostates. All surgical procedures were successfully completed with the Revoi in 100% of cases. In the present study, we chose the RS-RARP approach instead of the standard RARP approach not only to demonstrate the capabilities of the Revo-i system, but also because the leader of this research project, K.H.R. has no longer performed the standard RARP approach since late 2012.
With regard to baseline characteristics, the median prostate weight in the present study was 25.3 g. Generally, Asian men have smaller prostates than Western men, which explains the low prostate weight [12] . Previously, we investigated the impact of prostate volume on the peri-operative, continence and early oncological outcomes of RS-RARP (Table 1) . We found that patients with prostate volumes >60 mL were at risk of higher EBL, blood transfusion and longer length of hospital stay [13] . This was attributable to the limited working space during surgery, which may be more apparent in men with large prostates and a broad prostate base with a wide vascular pedicle, which increases the complexity of dissection.
Assessment of the peri-operative outcomes in the present study showed that the mean (SD) EBL was 320 AE 321 mL which is consistent with a recent study by Yaxley et al. [14] , who reported a mean EBL of 443 AE 294 mL after the standard RARP (n = 157) [14] ; however, the peri-operative transfusion rate was higher in the present study (17.6%) compared with their report (1%). There are several possible reasons for this big difference in transfusion rate. First, the small number of patients included (results might change if the number was higher). Second, the intra-operative blood transfusion rate (5.9%) was attributable to one very challenging case with a history of previous rectal cancer surgery, in which severe adhesions were present and difficulty in dissecting the posterior prostatic surface and freeing of the neurovascular bundle away from the rectum arose. Lastly, there was no specified criterion for postoperative blood transfusion, and two transfusions were carried out at the discretion of the surgeon if postoperative serum haemoglobin was <10 g/dL, which might be overtreatment.
In the present study we achieved similar results to those of previous RS-RARP reports using the da Vinci system [13, 15, 16] . In the present study the PSM rate was 18.8% in pT2 disease and 100% in pT3 disease, in a recent randomized control trial by Dalela et al. [16] , the PSM rate was 25% among patients with low-and intermediate-risk PCa treated with RS-RARP. Galfano et al. [15] reported PSM rates of 15% Likert scoring degree: strongly disagree (1 point), disagree (2 points), neither agree nor disagree (3 points), agree (4 points), and strongly agree (5 points).
and 45% in pT2 and pT3 pathological specimens, respectively. In our previous RS-RARP study using the da Vinci surgical system there was a PSM rate of 12.5% in pT2 disease [17] , which was lower than the rate of 18.8% in pT2 disease in the present study. This might be attributable to the small number of patients (n = 17) included in the present study compared with the previous report (n = 50), which might not be representative of the actual PSM rate if the number increased. The continence rate (no pad use) in the present study was 70.6% at 3 months. When we use a definition similar to that used in previous studies (no pad or one safety pad) the continence rate becomes 88.2% at 3 months. In the previous studies, the continence rate was 95% at 3 months [16] and 96% at 1 year [15] . This small difference can be explained by the small sample size in our cohort.
From an oncological point of view, we did not perform any type of PLND in patients with high-risk PCa for fear of inadvertent pelvic vessel injury while using the new robotic system and to ensure maximum intra-operative patient safety. We fully discussed this issue with patients before surgery and informed them that surgery might miss some microscopic nodal involvement, if present, and that they would need very strict follow-up to detect early BCR and/or local recurrence that would be treated with adjuvant therapy. Interestingly, a recent systematic review did not show additional benefit of performing any type of PLND during radical prostatectomy for any oncological outcomes including BCR and survival [18] ; however, PLND may be curative for certain patients with limited lymph node involvement that is completely removed at the time of surgery (direct effect) or may represent an accurate tool for identification of patients with pN1 disease, who might benefit from early adjuvant treatments that improve survival outcomes (indirect effect) [18] .
In the present study, one patient developed BCR at 3 months; the remaining patients had nadir PSA level. Although, the short follow-up period was not enough to evaluate the full oncological safety, the early results were encouraging. In fact, most patients in the present study had low-and intermediate-risk PCa. Thus, these early oncological results should be interpreted very carefully before deciding to treat patients with high-risk PCa using Revo-i. A longer follow-up period, a greater number of patients, and more clinical research is needed before the application of Revo-i in all patients with PCa.
The main differences in the characteristics and specifications between the da Vinci and Revo-i robotic surgical systems have been reported previously [8] . Regarding the new robotic specific complications and malfunctions during the study, no major technical problems occurred during the study and most could be managed immediately with no reported risk to patients. These problems can be summarized as follows: the robot arm was not sensitive enough to recognize the instruments and we had to insert the instruments sometimes repeatedly to overcome this; the scissors were not sharp enough to cut the tissue as easily as da Vinci scissors, and to overcome this problem we had to prepare two or three additional scissors for the bedside table; the operation was sometimes interrupted because of the safety feature whereby the robot stopped if the speed of the surgeon's hand movement exceeded the optimum speed adjusted for the robot, and the surgeon's performance was restricted by this as he had to wait for a while to resume surgery again; and the size of the robotic arm is larger than that of the da Vinci robot, requiring more precaution from the bedside assistant to ensure adequate space between the arms to minimize the occurrence of external and internal collisions. The camera resolution was outstanding, however, and fewer foggy effects of cautery were present. All the minor technical problems were received and recorded by the company engineer team, so solutions can be sought for the next commercial Revo-i version.
During the past decade, robotic surgery has emerged as a suitable treatment option in the field of gastrointestinal, urological and gynaecological surgery. The da Vinci system has had a great impact on the initiation and development of robot surgery. As a result, more than 3 700 da Vinci systems have been adopted at hospital and medical centres worldwide [5] . Recently, many preclinical stage studies or clinical studies have been carried out in animals or humans using different robotic systems [19] [20] [21] ; however, the only commercially available robotic surgical system apart from the da Vinci system is the Telelap ALF-X â (Sofar, Milan, Italy). Certainly, the high technical standards of four da Vinci generations have set a high bar for upcoming devices. New platforms will need to be critically assessed, and their performance necessarily compared with the current 'gold standard' da Vinci. Currently, robotic surgery is considered to be surgery using the da Vinci system. This standardization has led to high operation costs for patients and expensive annual service costs [6] . The need for the emergence of new robotic surgery systems is significant, therefore, not only in terms of technology but also the fact that many more people would benefit from lowering the cost of surgery.
The present study has some limitations. First, no PLND was performed for reasons of intra-operative patient safety, which was a major drawback; we preferred to avoid dissection of the pelvic vessels during the first clinical use of the Revo-i. Second, the surgery was performed by an expert robotic surgeon and at high-volume centre, thus the results may not be generalizable to small robotic surgery centres. No costeffectiveness comparison with the da Vinci was carried out because the company has not yet decided the commercial price, and the robotic system, supplements, and all instruments used were funded for the trial.
Strengths of the present study include the fact that it is the first to examine the performance of a new robotic surgical system (Revo-i) in the treatment of patients with PCa. The fact that it was a prospective study with strict follow-up for all patients is another strength. Choosing RS-RARP, which is a surgically demanding procedure, helps assess the accuracy, proficiency and safety of the new robot in performing surgery in humans. Based on the successful results of the present study, the Revo-i system received approval for commercial use from the Korean government in August 2017. The emergence of this new robotic surgical system could lower the cost of applying robotic surgery in different parts of the world where robotic surgery is currently not available. Lastly, there is no doubt that the present study will have a great impact on the future of robotic surgery in urology practice and other surgical fields. It will help to increase research into robotic surgery, allow more competition between the new robot manufacturers, advance robotic technology, and further robotic innovations, which are expected to provide maximum benefits to patients treated with robotic surgery and improve their health-related quality of life, which is the primary goal for all concerned.
In conclusion, the first human study on the treatment of patients with localized PCa using Revo-i robotic surgical system was carried out successfully. The clinical efficacy and safety of the Revo-i robotic surgical system needs to be tested further in various surgical procedures in near future.
